Sentence examples for some recent trials from inspiring English sources

Major reasons for failure of some recent trials are the inclusion of patients as subjects who are "symptomatic volunteers", patients who barely meet the minimal level of qualification, or those who are admitted because of a tendency on the part of clinicians, consciously or unconsciously, to lower their threshold for perceiving symptoms.

In some recent trials enhanced patient interview techniques consisting of Structured Interview Guide for the Montgomery Asberg Depression Rating Scale (SIGMA) interviews, audiotaping of patient interviews and 'central' appraisal with Rater Applied Performance Scale (RAPS) criteria have been implemented in the hope of increasing reliability and thus reducing the placebo response.

PURPOSE: Although numerous clinical trials have demonstrated the efficacy and tolerability of erythropoiesis-stimulating agents (ESAs) in patients with chemotherapy-induced anemia (CIA), results of some recent trials and one meta-analysis have suggested that ESAs may negatively impact survival and/or disease control in patients with cancer.

Some recent trials (11, 12, 16– 18) likely supported the absence of this association.

Some recent trials of aggressive therapies exclude individuals not able to demonstrate the capacity to provide consent.

However, the results of some recent trials indicate that there is no guarantee that the assumption will hold.

That systematic review was conducted through January of 2007, excluding some more recent trials discussed below.

Therapeutic hypothermia for TBI has been subject to a number of trials of varying size and quality, however, some more recent trials, such as Marion [ 25] and Clifton [ 29], have been of better methodological quality.

Supported by some large recent trials, concomitant chemoradiation therapy is increasingly used for stage III and IV disease, and postoperatively in those with poor prognostic features and who are fit enough for this arduous combination.

This review briefly discusses some of the challenges presented in designing a clinical trial of therapies for AHFS and to describe some of the recent trials with respect to these issues in established drugs (such as milrinone, dobutamine, nitroglycerin, nitroprusside, and nesiritide) that have been approved by the US Food and Drug Administration FDAA).

There is also some evidence from recent trials to suggest a possible link between high plasma concentrations of omega-3 fatty acids and increased risk of prostate cancer [ 70, 71].